{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:14:03Z","timestamp":1781619243929,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The aim of the study was to compare [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FACBC positron emission tomography (PET)-based radiotherapy (RT) volumes to magnetic resonance (MR)-based volumes and investigate the potential impact of including [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FACBC PET in RT treatment planning for gliomas.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      MR- and PET-defined gross tumor volumes (GTVs) were independently contoured on pre-operative [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FACBC PET\/MR images in 24 patients with primary or recurrent low- or high-grade glioma. MR GTVs were defined from regions of contrast-enhancement on T1-weighted (ce-T1) sequences. For non-enhancing tumors or non-enhancing tumor components, regions of FLAIR hyperintensity were also included. PET-based GTVs were delineated using a tumor-to-background ratio (TBR) threshold of 2. GTVs were expanded by an isotropic margin to form clinical target volumes (CTVs). Volumetric analysis was performed using size comparisons, Dice coefficients (DC), overlap coefficients (OC) and Hausdorff distances (HD).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PET GTVs were overall significantly smaller than MR GTVs, with median values of 14.8 ccm (6.5\u201326.7 ccm) and 28.5 ccm (17.2\u201362.7 ccm), respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011). No significant volume difference was found between PET and MR volumes when MR volumes were based on ce-T1 only, but PET-based GTVs and CTVs were significantly smaller than MR-based GTVs and CTVs when the latter included FLAIR hyperintensity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Similarity metrics showed a high degree of concordance between PET and MR volumes in cases where MR volumes were based on ce-T1 only, particularly for CTVs (DC: 0.88 (0.82\u20130.94), OC: 0.98 (0.96\u20130.99), HD: 0.86\u00a0cm (0.7\u20131.4\u00a0cm)). In comparison, for cases including FLAIR hyperintensity, MR CTVs had a high overlap with PET CTVs (OC: 0.99 (0.96\u20130.99)), but otherwise significantly lower degree of concordance (DC: 0.66 (0.46\u20130.81),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01, HD: 2.65\u00a0cm (2.22\u20133.85\u00a0cm),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FACBC PET underestimates tumor extension compared to FLAIR in contrast negative tumors and tumors containing non-enhancing components, indicating reduced sensitivity to low-grade tumor tissue and microscopic tumor infiltration. Inclusion of [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FACBC PET as supplement to MR in RT planning for glioma could however help identify regions of highly malignant tumor, to facilitate target volume reduction and dose escalation strategies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-025-02752-2","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:56:14Z","timestamp":1763736974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential impact of [18F]-FACBC PET in radiotherapy target definition of glioma"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3627-6233","authenticated-orcid":false,"given":"Benedikte Emilie","family":"Vindstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tora Skeidsvoll","family":"Solheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"St\u00e5hl-Kornerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Skeidsvoll","family":"Solheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Magnus","family":"Berntsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Kjelsberg","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Karlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Live","family":"Eikenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"10145","key":"2752_CR1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(18)30990-5","volume":"392","author":"S Lapointe","year":"2018","unstructured":"Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432\u201346.","journal-title":"Lancet"},{"issue":"10","key":"2752_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"key":"2752_CR3","doi-asserted-by":"publisher","first-page":"110594","DOI":"10.1016\/j.radonc.2024.110594","volume":"202","author":"BG Baumert","year":"2025","unstructured":"Baumert BG, Jaspers PM, Keil J, Galldiks VC, Izycka-Swieszewska N, Timmermann E. ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma. Radiother Oncol. 2025;202:110594.","journal-title":"Radiother Oncol"},{"key":"2752_CR4","doi-asserted-by":"crossref","unstructured":"Niyazi M, Andratschke N, Bendszus M, Chalmers AJ, Erridge SC, Galldiks N, et al. ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiother Oncol. 2023;184.","DOI":"10.1016\/j.radonc.2023.109663"},{"issue":"1","key":"2752_CR5","doi-asserted-by":"publisher","first-page":"e0169292","DOI":"10.1371\/journal.pone.0169292","volume":"12","author":"O Eidel","year":"2017","unstructured":"Eidel O, Burth S, Neumann JO, Kieslich PJ, Sahm F, Jungk C, et al. Tumor infiltration in enhancing and Non-Enhancing parts of glioblastoma: A correlation with histopathology. PLoS ONE. 2017;12(1):e0169292.","journal-title":"PLoS ONE"},{"issue":"7","key":"2752_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/neuonc\/nos128","volume":"14","author":"RF Barajas Jr","year":"2012","unstructured":"Barajas RF Jr, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, et al. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR imaging. Neuro Oncol. 2012;14(7):942\u201354.","journal-title":"Neuro Oncol"},{"issue":"5","key":"2752_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2967\/jnumed.122.264859","volume":"64","author":"N Galldiks","year":"2023","unstructured":"Galldiks N, Lohmann P, Fink GR, Langen KJ. Amino acid PET in neurooncology. J Nucl Med. 2023;64(5):693\u2013700.","journal-title":"J Nucl Med"},{"issue":"8","key":"2752_CR8","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/S1470-2045(25)00193-7","volume":"26","author":"N Galldiks","year":"2025","unstructured":"Galldiks N, Lohmann P, Aboian M, Barajas RF Jr., Breen WG, Ivanidze J, et al. Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas. Lancet Oncol. 2025;26(8):e436\u201347.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2752_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00259-023-06437-4","volume":"51","author":"A Karlberg","year":"2024","unstructured":"Karlberg A, Pedersen LK, Vindstad BE, Skjulsvik AJ, Johansen H, Solheim O, et al. Diagnostic accuracy of anti-3-[18F]-FACBC PET\/MRI in gliomas. Eur J Nucl Med Mol Imaging. 2024;51(2):496\u2013509.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2752_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00259-019-04433-1","volume":"47","author":"L Michaud","year":"2020","unstructured":"Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, et al. (18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2020;47(6):1353\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2752_CR11","first-page":"85","volume":"5","author":"N Tsuyuguchi","year":"2017","unstructured":"Tsuyuguchi N, Terakawa Y, Uda T, Nakajo K, Kanemura Y. Diagnosis of brain tumors using amino acid transport PET imaging with (18)F-fluciclovine: A comparative study with L-methyl-(11)C-methionine PET imaging. Asia Ocean J Nucl Med Biol. 2017;5(2):85\u201394.","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"14","key":"2752_CR12","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.3390\/cancers16142581","volume":"16","author":"BE Vindstad","year":"2024","unstructured":"Vindstad BE, Skjulsvik AJ, Pedersen LK, Berntsen EM, Solheim OS, Ingebrigtsen T, et al. Histomolecular validation of [18F]-FACBC in gliomas using Image-Localized biopsies. Cancers (Basel). 2024;16(14):2581.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2752_CR13","first-page":"1188","volume":"17","author":"BM Ellingson","year":"2015","unstructured":"Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, et al. Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol. 2015;17(9):1188\u201398.","journal-title":"Neuro Oncol"},{"issue":"3","key":"2752_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11060-015-1908-9","volume":"125","author":"SJ Fouke","year":"2015","unstructured":"Fouke SJ, Benzinger T, Gibson D, Ryken TC, Kalkanis SN, Olson JJ. The role of imaging in the management of adults with diffuse low grade glioma. J Neurooncol. 2015;125(3):457\u201379.","journal-title":"J Neurooncol"},{"key":"2752_CR15","doi-asserted-by":"publisher","first-page":"117221","DOI":"10.1016\/j.neuroimage.2020.117221","volume":"222","author":"CN Ladefoged","year":"2020","unstructured":"Ladefoged CN, Hansen AE, Henriksen OM, Bruun FJ, Eikenes L, \u00d8en SK, et al. AI-driven Attenuation correction for brain PET\/MRI: clinical evaluation of a dementia cohort and importance of the training group size. NeuroImage. 2020;222:117221.","journal-title":"NeuroImage"},{"key":"2752_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.neuroimage.2016.12.010","volume":"147","author":"CN Ladefoged","year":"2017","unstructured":"Ladefoged CN, Law I, Anazodo U, St Lawrence K, Izquierdo-Garcia D, Catana C, et al. A multi-centre evaluation of eleven clinically feasible brain PET\/MRI Attenuation correction techniques using a large cohort of patients. NeuroImage. 2017;147:346\u201359.","journal-title":"NeuroImage"},{"issue":"2","key":"2752_CR17","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6(2):65\u201370.","journal-title":"Scand J Stat"},{"key":"2752_CR18","unstructured":"Cohen J. Things I have learned (so far). American Psychological Association; 2016."},{"issue":"3","key":"2752_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2307\/1932409","volume":"26","author":"LR Dice","year":"1945","unstructured":"Dice LR. Measures of the amount of Ecologic association between species. Ecology. 1945;26(3):297\u2013302.","journal-title":"Ecology"},{"issue":"9","key":"2752_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1109\/34.232073","volume":"15","author":"DP Huttenlocher","year":"1993","unstructured":"Huttenlocher DP, Klanderman GA, Rucklidge WJ. Comparing images using the hausdorff distance. IEEE Trans Pattern Anal Mach Intell. 1993;15(9):850\u201363.","journal-title":"IEEE Trans Pattern Anal Mach Intell"},{"issue":"4","key":"2752_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/neuonc\/nox193","volume":"20","author":"BM Ellingson","year":"2018","unstructured":"Ellingson BM, Wen PY, Cloughesy TF. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro Oncol. 2018;20(4):457\u201371.","journal-title":"Neuro Oncol"},{"key":"2752_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10014-010-0275-7","volume":"27","author":"T Yamahara","year":"2010","unstructured":"Yamahara T, Numa Y, Oishi T, Kawaguchi T, Seno T, Asai A, et al. Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging. Brain Tumor Pathol. 2010;27:81\u20137.","journal-title":"Brain Tumor Pathol"},{"key":"2752_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1748-717X-3-44","volume":"3","author":"DC Weber","year":"2008","unstructured":"Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M, et al. [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol. 2008;3:44.","journal-title":"Radiat Oncol"},{"issue":"1","key":"2752_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijrobp.2005.01.045","volume":"63","author":"AL Grosu","year":"2005","unstructured":"Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, et al. L-(methyl-11\u00a0C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(1):64\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2752_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.radonc.2019.12.005","volume":"145","author":"DF Fleischmann","year":"2020","unstructured":"Fleischmann DF, Unterrainer M, Sch\u00f6n R, Corradini S, Maih\u00f6fer C, Bartenstein P, et al. Margin reduction in radiotherapy for glioblastoma through (18)F-fluoroethyltyrosine PET? - A recurrence pattern analysis. Radiother Oncol. 2020;145:49\u201355.","journal-title":"Radiother Oncol"},{"issue":"4","key":"2752_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12149-024-01901-z","volume":"38","author":"H Niitsu","year":"2024","unstructured":"Niitsu H, Fukumitsu N, Tanaka K, Mizumoto M, Nakai K, Matsuda M, et al. Methyl-(11)C-L-methionine positron emission tomography for radiotherapy planning for recurrent malignant glioma. Ann Nucl Med. 2024;38(4):305\u201314.","journal-title":"Ann Nucl Med"},{"key":"2752_CR27","doi-asserted-by":"publisher","first-page":"699360","DOI":"10.3389\/fonc.2021.699360","volume":"11","author":"D Sipos","year":"2021","unstructured":"Sipos D, L\u00e1szl\u00f3 Z, T\u00f3th Z, Kov\u00e1cs P, Toll\u00e1r J, Gulyb\u00e1n A, et al. Additional value of 18F-FDOPA amino acid analog Radiotracer to irradiation planning process of patients with glioblastoma multiforme. Front Oncol. 2021;11:699360.","journal-title":"Front Oncol"},{"issue":"8","key":"2752_CR28","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/neuonc\/not002","volume":"15","author":"DH Pafundi","year":"2013","unstructured":"Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013;15(8):1058\u201367.","journal-title":"Neuro Oncol"},{"issue":"10","key":"2752_CR29","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1136\/jnnp.2003.028480","volume":"75","author":"K Miwa","year":"2004","unstructured":"Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T, et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry. 2004;75(10):1457\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"2752_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ejrad.2008.04.018","volume":"71","author":"CJ Ledezma","year":"2009","unstructured":"Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, et al. 18F-FDOPA PET\/MRI fusion in patients with primary\/recurrent gliomas: initial experience. Eur J Radiol. 2009;71(2):242\u20138.","journal-title":"Eur J Radiol"},{"issue":"1","key":"2752_CR31","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1038\/s41467-025-58356-7","volume":"16","author":"KJ Chung","year":"2025","unstructured":"Chung KJ, Abdelhafez YG, Spencer BA, Jones T, Tran Q, Nardo L, et al. Quantitative PET imaging and modeling of molecular blood-brain barrier permeability. Nat Commun. 2025;16(1):3076.","journal-title":"Nat Commun"},{"issue":"3","key":"2752_CR32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11307-013-0693-0","volume":"16","author":"S Oka","year":"2014","unstructured":"Oka S, Okudaira H, Ono M, Schuster DM, Goodman MM, Kawai K, et al. Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[methyl-11\u00a0C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol. 2014;16(3):322\u20139.","journal-title":"Mol Imaging Biol"},{"key":"2752_CR33","first-page":"249","volume":"47","author":"M Ono","year":"2015","unstructured":"Ono M, Doi Y, Oka S, Okudaira H, Schuster DM, Goodman MM, et al. Transport mechanism of the amino acid positron emission tomography tracer [18F]fluciclovine and its application to glioma diagnosis. Drug Metab Rev. 2015;47:249.","journal-title":"Drug Metab Rev"},{"key":"2752_CR34","doi-asserted-by":"crossref","unstructured":"Fuchs BC, Bode BP, editors. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin cancer biol. Elsevier; 2005.","DOI":"10.1016\/j.semcancer.2005.04.005"},{"key":"2752_CR35","doi-asserted-by":"publisher","first-page":"109768","DOI":"10.1016\/j.radonc.2023.109768","volume":"188","author":"MH Seaberg","year":"2023","unstructured":"Seaberg MH, Kazda T, Youland RS, Laack NN, Pafundi DH, Anderson SK, et al. Dosimetric patterns of failure in the era of novel chemoradiotherapy in newly-diagnosed glioblastoma patients. Radiother Oncol. 2023;188:109768.","journal-title":"Radiother Oncol"},{"key":"2752_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.radonc.2020.11.019","volume":"156","author":"JPM Jaspers","year":"2021","unstructured":"Jaspers JPM, M\u00e9ndez Romero A, Wiggenraad R, Compter I, Eekers DBP, Nout RA, et al. Pattern of failure in IDH mutated, low grade glioma after radiotherapy \u2013 Implications for margin reduction. Radiother Oncol. 2021;156:43\u20138.","journal-title":"Radiother Oncol"},{"issue":"3 Suppl","key":"2752_CR37","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ijrobp.2009.02.091","volume":"76","author":"YR Lawrence","year":"2010","unstructured":"Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S20\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2752_CR38","doi-asserted-by":"publisher","first-page":"109435","DOI":"10.1016\/j.radonc.2022.11.024","volume":"181","author":"G Minniti","year":"2023","unstructured":"Minniti G, Tini P, Giraffa M, Capone L, Raza G, Russo I, et al. Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis. Radiother Oncol. 2023;181:109435.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2752_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.prro.2018.06.001","volume":"9","author":"K Guram","year":"2019","unstructured":"Guram K, Smith M, Ginader T, Bodeker K, Pelland D, Pennington E, et al. Using Smaller-Than-Standard radiation treatment margins does not change survival outcomes in patients with High-Grade gliomas. Pract Radiat Oncol. 2019;9(1):16\u201323.","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"2752_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/COC.0b013e318271ae03","volume":"37","author":"AK Paulsson","year":"2014","unstructured":"Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, et al. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncology: Cancer Clin Trials. 2014;37(2):177\u201381.","journal-title":"Am J Clin Oncology: Cancer Clin Trials"},{"issue":"3","key":"2752_CR41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/nop\/npae009","volume":"11","author":"MT Yilmaz","year":"2024","unstructured":"Yilmaz MT, Kahvecioglu A, Yedekci FY, Yigit E, Ciftci GC, Kertmen N, et al. Comparison of different target volume delineation strategies based on recurrence patterns in adjuvant radiotherapy for glioblastoma. Neuro-Oncology Pract. 2024;11(3):275\u201383.","journal-title":"Neuro-Oncology Pract"},{"issue":"3","key":"2752_CR42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11060-024-04824-x","volume":"170","author":"O Gal","year":"2024","unstructured":"Gal O, Mehta MP, Kotecha R. Radiotherapeutic advances in the management of glioblastoma. J Neurooncol. 2024;170(3):509\u201320.","journal-title":"J Neurooncol"},{"issue":"2","key":"2752_CR43","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijrobp.2021.05.001","volume":"111","author":"R Singh","year":"2021","unstructured":"Singh R, Lehrer EJ, Wang M, Perlow HK, Zaorsky NG, Trifiletti DM, et al. Dose escalated radiation therapy for glioblastoma multiforme: an international systematic review and Meta-Analysis of 22 prospective trials. Int J Radiat Oncol Biol Phys. 2021;111(2):371\u201384.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2752_CR44","doi-asserted-by":"crossref","unstructured":"Miwa K, Matsuo M, Ogawa SI, Shinoda J, Asano Y, Ito T, et al. Hypofractionated high-dose irradiation with positron emission tomography data for the treatment of glioblastoma multiforme. Biomed Res Int. 2014;2014.","DOI":"10.1155\/2014\/407026"},{"issue":"5","key":"2752_CR45","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.ijrobp.2021.03.032","volume":"110","author":"NN Laack","year":"2021","unstructured":"Laack NN, Pafundi D, Anderson SK, Kaufmann T, Lowe V, Hunt C, et al. Initial results of a phase 2 trial of 18F-DOPA PET-Guided Dose-Escalated radiation therapy for glioblastoma. Int J Radiation Oncology*Biology*Physics. 2021;110(5):1383\u201395.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"issue":"14","key":"2752_CR46","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1158\/1078-0432.CCR-22-0171","volume":"28","author":"M Harat","year":"2022","unstructured":"Harat M, Blok M, Miechowicz I, Wiatrowska I, Makarewicz K, Ma\u0142kowski B. Safety and efficacy of irradiation boost based on 18F-FET-PET in patients with newly diagnosed glioblastoma. Clin Cancer Res. 2022;28(14):3011\u201320.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2752_CR47","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12553-024-00842-x","volume":"14","author":"A Mairani","year":"2024","unstructured":"Mairani A. Innovative approaches to enhance high-LETd tumor targeting in carbon ion radiotherapy. Health Technol. 2024;14(5):889\u201394.","journal-title":"Health Technol"},{"key":"2752_CR48","doi-asserted-by":"crossref","unstructured":"Garrido-Hernandez G, Ytre-Hauge KS, Winter RM, Danielsen S, Alsaker MKD, Redalen KR, et al. In silico interim adaptation of proton therapy in head and neck cancer by simultaneous dose and linear energy transfer escalation. Int J Radiat Oncol Biol Phys. 2025.","DOI":"10.1016\/j.ijrobp.2025.02.015"},{"issue":"6","key":"2752_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.21037\/cco-22-92","volume":"11","author":"KM Goff","year":"2022","unstructured":"Goff KM, Zheng C, Alonso-Basanta M. Proton radiotherapy for glioma and glioblastoma. Chin Clin Oncol. 2022;11(6):46.","journal-title":"Chin Clin Oncol"},{"issue":"6","key":"2752_CR50","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2967\/jnumed.106.035774","volume":"48","author":"M Soret","year":"2007","unstructured":"Soret M, Bacharach SL, Buvat I. Partial-Volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932\u201345.","journal-title":"J Nucl Med"},{"issue":"8","key":"2752_CR51","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/RLU.0000000000002641","volume":"44","author":"TV Bogsrud","year":"2019","unstructured":"Bogsrud TV, Londalen A, Brandal P, Leske H, Panagopoulos I, Borghammer P, et al. 18F-Fluciclovine PET\/CT in suspected residual or recurrent High-Grade glioma. Clin Nucl Med. 2019;44(8):605\u201311.","journal-title":"Clin Nucl Med"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02752-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02752-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02752-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:18:28Z","timestamp":1781615908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-025-02752-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2752"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02752-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Ethics Committee (REK South East Norway, reference numbers: 2016\/279 and 2018\/2243). All participants included in the study gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants gave informed consent for publication of the images presented in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}